Not Signed In -
Gamma Knife Treatment |
|
|
Clinical Trial: A Study of the Safety and Clinical Effects of Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis (IPF)
This study has been completed.
|
Purpose
Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with corticosteroids.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Idiopathic Pulmonary Fibrosis | Drug: Interferon-gamma 1b | Phase II |
MedlinePlus related topics: Pulmonary Fibrosis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon gamma-1b Administered Subcutaneously to Patients with IPF Followed by an Open-Label Extension
Expected Total Enrollment: 30
Study start: November 2001
Eligibility
Ages Eligible for Study: 20 Years - 79 Years, Genders Eligible for Study: Both
Criteria
Location Information
California
UCLA, Dept. of Medicine, Los Angeles, California, 90095, United States
More Information
Record last reviewed: January 2003
Last Updated: October 13, 2004
Record first received: October 9, 2002
ClinicalTrials.gov Identifier: NCT00047658
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
